Morgan Stanley analyst Connor Lynagh maintains Phillips 66 (NYSE:PSX) with a Equal-Weight and raises the price target from $100 to $105.
Biohaven Pharmaceutical Q2 EPS $(2.62) Beats $(2.74) Estimate, Sales $92.93M Beat $78.13M Estimate
Biohaven Pharmaceutical (NYSE:BHVN) reported quarterly losses of $(2.62) per share which beat the analyst consensus estimate of $(2.74) by 4.38 percent. This is a 2.75 percent decrease over losses of $(2.55) per share
